At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 52 enrolled
Drug / intervention
Cilofexor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects With Primary Sclerosing Cholangitis Without Cirrhosis
In Brief
A Phase 2 clinical trial evaluating Cilofexor and Placebo to match cilofexor for Primary Sclerosing Cholangitis. Completed, enrolled 52 participants across 23 sites in 4 countries.
Detailed Summary
The primary objective of this study is to evaluate the safety and tolerability of cilofexor in adults with primary sclerosing cholangitis (PSC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Sclerosing Cholangitis
CountriesAustria, Canada, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartNov 2016
Primary CompletionFeb 2018
Study CompletionMay 2020
TodayJul 2026
First PostedOct 24, 2016
Enrollment StartNov 29, 2016
Primary CompletionFeb 28, 2018
Study CompletionMay 18, 2020
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 9.7 years ago
Interventions
Cilofexordrug
Tablet(s) administered orally once daily with food
Placebo to match cilofexordrug
Tablet(s) administered orally once daily with food